If this is your company, CONTACT US to activate Packbase™ software to build your portal.

    Webpackaging logo

    Aptar Pharma Completes First Phase of Global Injectables Expansion Program

    Quick Contact
    • Aptar Pharma
    Aptar Pharma Completes First Phase of Global Injectables Expansion Program
    Europe, France, Switzerland, France, Health, Pharmaceuticals, Primary Packaging, Bottles, Bottles - Vials, Stoppers, Flexibles, Film, Sheet, Drug Delivery Devices, Active, Smart Packaging, Sustainable Packaging, Plastic, Plastic - Film, Environmental Services, Waste Management Services

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that it has delivered the first phase of its previously announced expansion program of approximately $180 million USD to meet growing customer capacity needs for injection system solutions.

    The multisite, international expansion project began in 2020 and is intended to significantly boost capacity across all product lines, ultimately enabling Aptar Pharma to produce over 10 billion injectable component units annually when completed.

    “Our planned expansion program proved timely and was expedited by the arrival of the COVID-19 pandemic,” said Gael Touya, President, Aptar Pharma. “The investments we’re making to expand manufacturing capacity and in new, digitalized processes will benefit our customers well into the future.”

    According to recent market research, injectables represents around 50% of the pharmaceutical drug development pipeline, with an estimated 40% market share. Between 2016 and 2021, injectables showed the largest drug sales growth of over 10% compound annual growth rate (CAGR 16-21), driven mainly by biologics and the demand for high value solutions, such as coated components like Aptar Pharma’s PremiumCoat®.

    Bold new capabilities

    Aptar Pharma’s investment encompasses the expansion and ramping up of Aptar Pharma manufacturing of PremiumCoat® ETFE film-coated components, PremiumFill® enhanced specification solutions, elastomer components and vial stoppers worldwide.

    The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint. The first phase of the PremiumCoat® capacity expansion is already operational in Granville, France and includes new ISO7 clean rooms and advanced robotics.

    An additional factory in Granville, France will be operational as of early 2024, which leverages the latest technology. US-based manufacturing capabilities will also be operational as of 2024 to better serve the local market. Further manufacturing expansion phases in both the US and France are also included in the program.

    A new, state-of-the-art manufacturing facility in Granville, France

    The establishment of a second manufacturing facility in Granville, France marks a new milestone in the transformation of Aptar Pharma and paves the way for a step change in capacity and high-tech efficiency. This highly automated factory will significantly increase production capacity to meet growing demand for elastomeric components, including PremiumCoat® solutions for enhanced drug/container compatibility. Partial funding of 13 million Euros for the building and expansion of Aptar Pharma’s European facilities was awarded as part of the French government’s Program of Investments for the Future.

    Meeting the needs of customers – and the planet

    To meet the ever-increasing market and customer requirements for even higher quality and reliability, Aptar Pharma is expanding its capabilities with robotization, digitalization and new clean rooms. Sustainability is a major consideration in Aptar Pharma’s expansion program, with the implementation of solar power production, water waste management and optimized energy consumption included.

    Forging closer partnerships with customers worldwide

    Aptar Pharma’s expansion was designed with customers in mind. By increasing the capacity and capabilities available through its regional manufacturing centers, Aptar Pharma is positioned to bring new levels of agility and responsiveness in order to meet the most demanding injectable customer needs around the world.

    “With this program, we’re transforming our organization to offer pharma companies of all sizes enhanced ways to fast-track and derisk their product development,” said Gabriel Zenker, President, Aptar Pharma Injectables. “In doing so, we’re fulfilling our commitment to making Aptar Pharma a first-choice, long-term partner for those seeking sustainable success for their drug development pipelines as part of our mission to shape the future of injectables together with our customers.”

    See also

    New FDA approved combination product with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, today announced that its VP3 multidose device is the delivery system for Glenmark’s Ryaltris™ nasal spray, which recently received New Drug Application (NDA) approval by the U.S. Food and Drug Administration. New FDA approved combination product for seasonal allergic rhinitis symptoms with Aptar Pharma's VP3 nasal spray system

    Aptar Pharma granted exclusive license option by Pharmaxis to develop and promote high payload dry powder inhaler

    Aptar Pharma have entered into an agreement with Pharmaxis, a clinical stage drug developer, under which Aptar Pharma has the option to acquire the worldwide rights to Pharmaxis’ proprietary high payload dry powder inhaler, Orbital. As part of the agreement, Aptar Pharma will evaluate the commercial applications for the Orbital device and further develop the prototype device to meet unmet market needs. Pharmaxis retains the rights to devices containing Orbital intellectual property used to deliver inhaled mannitol.

    Noble and Aptar Pharma launch AdhereIT, a connected medical device solution for disease management adherence and onboarding patients

    Noble and Aptar Pharma are pleased to announce the launch of AdhereIT - a connected, intuitive and user-friendly onboarding solution for the growing number of patients with chronic conditions who use autoinjectors to administer their medications at home. AdhereIT is the first fully interchangeable, connected add-on solution that can work across a multitude of autoinjector platforms.

    Aptar Seeks FDA Emergency Use Authorization for Decontaminating N95 Masks with ActivShield

    AptarGroup, Inc. is seeking U.S. FDA Emergency Use Authorization (EUA) for a solution that allows easy disinfecting of N95 filtering facepiece respirators (N95 masks) using their ActivShieldTM. The N95 masks are desperately needed by healthcare personnel due to the shortage of disposable masks during the COVID-19 pandemic and this simple disinfecting process lets medical professionals reuse the masks after decontaminition.

    Aptar Pharma’s Nasal Unidose Device approved by US FDA for new nasal seizure rescue treatment

    Aptar Pharma has announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the U.S. FDA as a rescue treatment for people with epilepsy aged six and older suffering from acute repetitive seizures. Aptar’s Unidose Liquid System is a single-use, ready-to-use one-step nasal delivery device which can deliver a formulation in an emergency situation quickly and easily.

    Aptar Pharma’s preservative-free multidose dispenser approved in the US for Allergan’s REFRESH RELIEVA PF artificial tear formulation

    Aptar Pharma has announced that its innovative, preservative-free multidose Ophthalmic Squeeze Dispenser is the delivery system for Allergan’s REFRESH RELIEVA PF, its new over-the-counter (OTC) preservative-free treatment for eye dryness in the U.S. This use reconfirms the market-leading position of Aptar Pharma’s Ophthalmic Squeeze Dispenser as the multidose delivery system for ophthalmic agents and formulations without preservatives.

    Aptar’s Nasal Unidose Device approved by US FDA

    AptarGroup, Inc, a global leader in dispensing and drug delivery solutions, has announced that its Unidose Powder System was recently approved by the U.S. Food and Drug Administration (FDA) for an intranasal, needle-free rescue treatment drug intended to treat severe hypoglycemia in people with diabetes. This marks the first FDA approval of a prescription drug using Aptar’s patented Unidose Powder System and is Aptar’s first combination of a drug delivery device with a protective active packaging container.

    Aptar acquires Nanopharm and Gateway Analytical, broadening pharma services platform to accelerate customer drug development

    AptarGroup, Inc. has announced that it has acquired two leading pharmaceutical services companies, Nanopharm Ltd. and Gateway Analytical LLC, for a combined enterprise value of approximately $50 million. The acquisitions are part of Aptar’s strategy to broaden its portfolio of services that support pharmaceutical and biotech customers to accelerate and derisk their complex product developments.

    Aptar Pharma's Freepod nasal spray device with GlaxoSmithKline's Otrivin wins prestigious WPO WorldStar 2019 award

    Aptar Pharma, a leading provider of innovative drug delivery systems, has announced that its patented Freepod nasal spray device with GlaxoSmithKline's Otrivin has received a Medical & Pharma category award at the World Packaging Organization (WPO) 2019 WorldStar Packaging Awards ceremony, which took place on May 15, 2019 in Prague. The WorldStar Awards Competition, hosted by the WPO, is considered to be one of the most prestigious international packaging awards events.

    • Company News
    • English
    • Modified 07 Nov 2022
    • Hits 411
    Conzept International
    Quadpack
    SR Packaging